Incyte

Incyte Pharmaceuticals Is Primed For A Run

Incyte Pharmaceuticals Is Primed For A Run

Seeking Alpha

JPMorgan Healthcare Conference Highlights: Incyte

JPMorgan Healthcare Conference Highlights: Incyte

Motley Fool

Biotech Portfolio Update: 2012 Summary And 2013 Outlook

Biotech Portfolio Update: 2012 Summary And 2013 Outlook

Seeking Alpha

Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short Covering

Hedge Funds Are Buying These 5 Healthcare Stocks With Heavy Short Covering

Seeking Alpha

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Incyte Achieves $50 Million Milestone as Oral JAK1/JAK2 Inhibitor Baricitinib Advances into Phase III Development for Rheumatoid Arthritis

Yahoo

Lilly arthritis drug shows durability in study

Lilly arthritis drug shows durability in study

Reuters

5 Low Risk, High Reward Biotech Stocks

5 Low Risk, High Reward Biotech Stocks

Motley Fool

The Wait Goes On At YM Biosciences

The Wait Goes On At YM Biosciences

Seeking Alpha

Why Incyte Could Be Headed Even Higher

Why Incyte Could Be Headed Even Higher

Motley Fool

Incyte